Days after luring Sanofi SA to a potential multi-billion-dollar diabetes deal, the pipeline of metabolic assets at Hanmi Pharmaceuticals Co. Ltd. caught the eye of another big pharma. Janssen Pharmaceuticals Inc., a unit of Johnson & Johnson, of New Brunswick, N.J., gained exclusive global rights outside Korea and China to develop and commercialize Hanmi's oxyntomodulin-based therapies, including HM12525A (LAPSGLP/GCG), a GLP-1/glucagon receptor dual agonist.